Oral sodium bicarbonate therapy given to patients with chronic kidney disease increases urinary pH but also increases urinary citrate levels, which may mitigate the risk for calcium phosphate stone formation.
Each 1 mEq/L increase in serum bicarbonate in kidney transplant recipients is associated with a 10% reduction in graft failure risk, a study found.
A study of patients with ADPKD found that each 1 mmol/L decrease in serum bicarbonate was significantly associated with a 21% increased risk for worsening kidney function.
Metabolic acidosis in patients with chronic kidney disease increases their likelihood of requiring dialysis or a kidney transplant, a study found.
Increased intake of fruits and vegetables corrects CKD-related metabolic acidosis as well as sodium bicarbonate supplements, but is associated with other health benefits, a new post hoc analysis found.
In patients with acidemia, hypobicarbonatemia conferred a considerable risk of kidney failure requiring renal replacement therapy after adjusting for potential confounders.
Veverimer is a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD.
Horizon Therapeutics announced the availability of Procysbi (cysteamine bitartrate) delayed-release oral granules in tear-open packets for the treatment of nephropathic cystinosis in patients aged 1 year and older.
The FDA has approved Procysbi (cysteamine bitartrate; Horizon Therapeutics) delayed-release oral granules, a new formulation for the treatment of nephropathic cystinosis in patients aged 1 year and older.
In a randomized, placebo-controlled trial that enrolled patients with chronic kidney disease stages 3 and 4, sodium bicarbonate did not significant affect sit-to-stand time or bone mineral density.
